From the World Health Organization:
Coronavirus treatment trials involving convalescent plasma have not been conclusive, World Health Organization (WHO) Chief Scientist Soumya Swaminathan said on Monday. Speaking at an online media briefing, she added that evidence of its success is “very low-quality” and that more testing is needed. Additionally, Swamnathan stated that monoclonal antibodies could also potentially be used to treat and prevent COVID-19, but that more trial results are needed for these treatments as well. The WHO chief scientist’s remarks come after United States President Donald Trump praised convalescent plasma treatment for COVID-19 as the Food and Drug Administration (FDA) issued an emergency use authorization. The British National Health Service also said in a statement earlier that results on convalescent plasma are inconclusive.
And from the NHS out of England:
Studies on using convalescent blood plasma for coronavirus treatment are “promising” but there is no clear evidence it is effective, the UK National Health Service (NHS) said in a statement on Monday. “The observational studies coming from America are promising and support the need for people to continue to donate convalescent plasma in England. However, they are not conclusive,” the statement said. On Sunday, United States President Donald Trump hailed the convalescent plasma therapy’s “incredible rate of success,” claiming it was proven “safe and effective.”